Jonas Mandel

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial

Lawrence A. Leiter, Bertrand Cariou, Dirk Müller‐Wieland et al. · Diabetes Obesity and Metabolism · 2017 · 140 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

Shahram Attarian, Jean‐Michel Vallat, Laurent Magy et al. · Orphanet Journal of Rare Diseases · 2014 · 124 citations · Full text

Medicine, Neurology, Pharmacology +15

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease

Peter P. Tóth, Jamie P. Dwyer, Christopher P. Cannon et al. · Kidney International · 2018 · 110 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy

Ilya Chumakov, Aude Milet, Nathalie Cholet et al. · Orphanet Journal of Rare Diseases · 2014 · 105 citations · Full text

Medicine, Neurology, Pharmacology +15

EMA - A R package for Easy Microarray data analysis

Nicolas Servant, Eléonore Gravier, Pierre Gestraud et al. · BMC Research Notes · 2010 · 53 citations · Full text

Life Sciences, Bioinformatics, Biostatistics +7